BioTrends Research Group has released findings from the second wave of its Zytiga (abiraterone acetate) report, in which a total of 121 U.S. urologists and medical oncologists were surveyed about their current awareness, trial and usage of Janssen Biotech’s Zytiga for discrete metastatic castrate-resistant prostate cancer (MCRPC) patient populations.
The study was fielded one year post launch of Zytiga in the United States
Compared with the first wave of research, oncologists now report a greater perceived efficacy of Zytiga in MCRPC patients pre-treated with docetaxel (Sanofi’s Taxotere, generics). Of those oncologists that are aware of Zytiga, the perceived overall survival achievement of Zytiga increased from 10.37 months in wave 1 to 11.01 months in wave 2. Similarly, amongst surveyed oncologists the reported time to prostate-specific antigen (PSA) progression increased wave-over-wave (7.0 vs. 7.9 months, respectively). However, oncologists still underestimate Zytiga’s performance compared with what has been demonstrated in pivotal clinical trials in the post-docetaxel setting. Nevertheless, wave-on-wave, the majority of surveyed physicians say that they have seen decreased use of mitoxantrone (Pfizer Novantrone, generics), and more than a third report decreased use of Sanofi’s Jevtana (cabazitaxel).
Janssen recently filed for FDA approval for Zytiga in the asymptomatic/minimally symptomatic, chemotherapy-naïve MCRPC setting; interviewed physicians are optimistic about Zytiga in this setting. In this wave of research, 20 percent of surveyed physicians have noticed a decrease in the use of Dendreon’s Provenge in the pre-chemotherapy MCRPC setting. The majority (79 percent), of all surveyed physicians believe that Zytiga approval in the first-line asymptomatic/minimally symptomatic MCRPC setting is likely or extremely likely. A greater proportion of oncologists believe approval is likely or extremely likely compared with urologists in both waves of research (83 percent vs. 75 percent in wave 2).
Although the majority of surveyed physicians are unaware of products that are in development for the treatment of MCRPC, of those that are, most point to Astellas/Medivation’s enzalutamide (formerly MDV-3100), Algeta/Bayer Healthcare’s Alpharadin and Exelixis’s Cabozantinib. Furthermore, more than a third of surveyed physicians select enzalutamide (formerly MDV-3100) as one of the top three emerging therapies that will pose the biggest competitive threat to Zytiga in the treatment of MCRPC. However concerns remain over Enzalutamides cardiotoxicity problems.
Compared with the first wave of research, oncologists now report a greater perceived efficacy of Zytiga in MCRPC patients pre-treated with docetaxel (Sanofi’s Taxotere, generics). Of those oncologists that are aware of Zytiga, the perceived overall survival achievement of Zytiga increased from 10.37 months in wave 1 to 11.01 months in wave 2. Similarly, amongst surveyed oncologists the reported time to prostate-specific antigen (PSA) progression increased wave-over-wave (7.0 vs. 7.9 months, respectively). However, oncologists still underestimate Zytiga’s performance compared with what has been demonstrated in pivotal clinical trials in the post-docetaxel setting. Nevertheless, wave-on-wave, the majority of surveyed physicians say that they have seen decreased use of mitoxantrone (Pfizer Novantrone, generics), and more than a third report decreased use of Sanofi’s Jevtana (cabazitaxel).
Janssen recently filed for FDA approval for Zytiga in the asymptomatic/minimally symptomatic, chemotherapy-naïve MCRPC setting; interviewed physicians are optimistic about Zytiga in this setting. In this wave of research, 20 percent of surveyed physicians have noticed a decrease in the use of Dendreon’s Provenge in the pre-chemotherapy MCRPC setting. The majority (79 percent), of all surveyed physicians believe that Zytiga approval in the first-line asymptomatic/minimally symptomatic MCRPC setting is likely or extremely likely. A greater proportion of oncologists believe approval is likely or extremely likely compared with urologists in both waves of research (83 percent vs. 75 percent in wave 2).
Although the majority of surveyed physicians are unaware of products that are in development for the treatment of MCRPC, of those that are, most point to Astellas/Medivation’s enzalutamide (formerly MDV-3100), Algeta/Bayer Healthcare’s Alpharadin and Exelixis’s Cabozantinib. Furthermore, more than a third of surveyed physicians select enzalutamide (formerly MDV-3100) as one of the top three emerging therapies that will pose the biggest competitive threat to Zytiga in the treatment of MCRPC. However concerns remain over Enzalutamides cardiotoxicity problems.
No comments:
Post a Comment